Objective To establish a drug quality control method for anti-interleukin-5 receptor(IL-5R) monoclonal antibody, in order to provide reference for the quality control of anti-IL-5R monoclonal antibody and other monoclonal antibodies targeting cytokine receptors.Methods The monoclonal antibody was determined for the peptide mapping by reversed-phase ultra-performance liquid chromatography(RP-UPLC), for the charge variants by imaged capillary isoelectric focusing(iCIEF), for the molecular size variants by reduced/non-reduced capillary electrophoresis sodium dodecyl sulfate(CESDS) and size exclusion chromatography(SEC), for the antibody-dependent cell-mediated cytotoxicity(ADCC) activity by reporter gene assay, and for the N-glycan profile by 2-aminobenzamide(2-AB) labeling method.Results The peptide mapping of the anti-IL-5R monoclonal antibody exhibited visual similarity to the reference standard. The iCIEF main peak content was(66. 94 ± 1. 52)%. The reduced CE-SDS heavy chain plus light chain content reached(96. 39 ± 0. 11)%, while the non-reduced main peak content was(96. 98 ± 0. 13)%. The SEC monomer content was(99. 62 ± 0. 06)%. The ADCC biological activity showed a relative potency of(90. 33 ± 15. 42)%. For the N-linked glycan profile, the G1/G0 ratio was(0. 14 ± 0. 00)%, and the high-mannose content was(1. 37 ± 0. 05)%.Conclusion A comprehensive quality control methodology was established for the anti-IL-5R monoclonal antibody, encompassing identity verification, purity analysis, biological activity, and N-linked glycosylation profiling, which provides reference for the development and quality control of therapeutic antibodies against this target and other cytokine receptors.